StockData
Monopar Therapeutics logo

Monopar Therapeutics (MNPR) stock

MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$71.06−0.91 (-1.26%)

Close on Nov 17, 2026Market cap $476.97MP/E –Yield –

Earnings

Monopar Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 26, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
$0.72
$0.48 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Monopar Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 26, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 12, 2026before the open––$0.72Release
Q2 FY2026ended Jun 30, 2026Aug 12, 2026during market hours––-$0.62Release
Q1 FY2026ended Mar 31, 2026May 14, 2026during market hours––-$0.46Release
Q4 FY2025ended Dec 31, 2025Mar 27, 2026during market hours––-$0.61Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025before the open––$0.48Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025before the open––-$0.35Release
Q1 FY2025ended Mar 31, 2025May 13, 2025before the open––-$0.38Release
Q4 FY2024ended Dec 31, 2024Mar 31, 2025before the open––-$2.23Release
Q3 FY2024ended Sep 30, 2024Nov 8, 2024before the open––-$0.37Release
Q2 FY2024ended Jun 30, 2024Aug 9, 2024before the open––$0.10Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open––-$0.10Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Monopar Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Monopar Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Monopar Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Update
  5. Update
  6. Update
  7. Update
  8. Update
  9. Results
  10. Update
  11. Update
  12. Results
  13. Update
  14. Results
  15. Update

See a number that looks wrong?